A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2018
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- Sponsors Sorrento Therapeutics
- 28 Mar 2018 Treatment of first cohort has been completed and treatment in second cohort is ongoing, according to a Sorrento Therapeutics media release.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 06 Jul 2017 New trial record